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activating the AMPK/SIRT1 pathway in skeletal
muscle of obese db/db mice
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Background: Telmisartan is a well-established angiotensin II type 1 receptor blocker that improves insulin
sensitivity in animal models of obesity and insulin resistance, as well as in humans. Telmisartan has been reported
to function as a partial agonist of the peroxisome proliferator-activated receptor (PPAR) γ, which is also targeted by
the nicotinamide adenine dinucleotide (NAD)-dependent deacetylase (SIRT1). Here, we investigated the pathways
through which telmisartan acts on skeletal muscle, in vitro as well as in vivo.
Methods: Nine-week-old male db/db mice were fed a 60% high-fat diet, with orally administrated either vehicle
(carboxymethyl-cellulose, CMC), 5 mg/kg telmisartan, or 5 mg/kg telmisartan and 1 mg/kg GW9662, a selective
irreversible antagonist of PPARγ, for 5 weeks. Effects of telmisartan on Sirt1 mRNA, AMPK phosphorylation, and NAD
+/NADH ratio were determined in C2C12 cultured myocytes.
Results and discussion: Telmisartan treatment improved insulin sensitivity in obese db/db mice fed a high-fat diet
and led to reduction in the size of hypertrophic pancreatic islets in these mice. Moreover, in vitro treatment with
telmisartan led to increased expression of Sirt1 mRNA in C2C12 skeletal muscle cells; the increase in Sirt1 mRNA in
telmisartan-treated C2C12 myoblasts occurred concomitantly with an increase in AMPK phosphorylation, an
increase in NAD+/NADH ratio, and increases in the mRNA levels of PGC1α, FATP1, ACO, and GLUT4.
Conclusions: Our results indicate that telmisartan acts through a PPARγ-independent pathway, but at least partially
exerts its effects by acting directly on skeletal muscle AMPK/SIRT1 pathways.
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The nicotinamide adenine dinucleotide (NAD)-dependent
deacetylase (SIRT1) has been reported to be involved in
protection against metabolic disorders as well as in enhan-
cing life span [1]. Evidence suggests that SIRT1 also plays
a fundamental role in the metabolism and differentiation
of skeletal muscle cells [2], and transgenic or knockout
Sirt1 mouse models have implicated the protein in protec-
tion of skeletal muscle against oxidative stress [3,4]. It has* Correspondence: mshimabukuro-ur@umin.ac.jp
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reproduction in any medium, provided the orbeen speculated that SIRT1 plays an important role in the
regulation of transcriptional networks in various critical
metabolic processes [1]. The SIRT1 signal seems to be
mediated by an increase in fatty acid oxidation by activa-
tion of AMP-activated protein kinase (AMPK) in skeletal
muscle [5]. The AMPK activators metformin [6] and
A-769662 [7], as well as resveratrol [8], a polyphenolic
SIRT1 activator, ameliorate insulin resistance in animals
given a high-fat diet.
Telmisartan is a well-established angiotensin II type 1
receptor (AT1) blocker that improves insulin sensitivity
in rodents that have received high-fat–containing diets
[9-12], as well as in diabetic [12] and nondiabetic
patients [13]. Telmisartan has been reported to functionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activated receptor (PPAR) γ, a member of the ligand-
activated nuclear receptor superfamily that is expressed
at high levels in adipose tissue [14]. PPARγ regulates
genes that modulate lipid utilization and storage, lipo-
protein metabolism, adipocyte differentiation, and insu-
lin action [14]. Thus, it is possible that the antidiabetic
effects of telmisartan depend largely on PPARγ-
dependent mechanisms [15]. PPARγ and the PPARγ
coactivator (PGC)-1α, which play key roles in various
metabolic disorders, are also known to be targeted by
SIRT1 [16,17], but the effects of telmisartan on SIRT1-
and PPARγ-signaling remain unclear.
In the present study, we investigated whether telmisar-
tan acts on skeletal muscle through an AMPK/SIRT1
pathway in skeletal muscle.
Materials and methods
Animals and experimental protocol
Study protocols were approved by the Committee on
Animal Research, the University of Tokushima, and have
been done on the basis of ethical principles and guide-
lines for experiments on animals (http://freedownload.is/
pdf/ethical-principles-and-guidelines-for-experiments-
on-animals-22328952.html). Nine-week-old male db/db
mice (Charles River Laboratories Japan Inc. Tokyo,
Japan) were fed a high-fat diet (HFD-60, Oriental Yeast
Co., Ltd., Tokyo) ad libitum for 5 weeks. HFD-60 contains
energy content 62% fat (lard 33, milk-casein 26, corn-
starch 16 g/100 g•diet; fatty acid 16:0 24.4, C18:0 13.8,
C:18:1 41.8, 18:2(n-6) 12.0 g/100 g of total fatty acids),
18% protein and 20% carbohydrate, compatible with the
AIN-93 G recommendations [18]. db/db mice were sepa-
rated into 3 groups and were orally administrated either
vehicle (carboxymethyl-cellulose, CMC), 5 mg/kg telmi-
sartan, or 5 mg/kg telmisartan and 1 mg/kg GW9662
(Sigma, St. Louis, MO), a selective irreversible antagonist
of PPARγ, once a day, for 5 weeks. Age-matched male wild
type +/+ mice (Charles River Laboratories Japan) fed a
normal diet, containing energy content 10% fat, 14% pro-
tein and 76% carbohydrate (AIN-93 M, Oriental Yeast Co.
Ltd.) were used as a control group.
We defined the dose usage of telmisartan and
GW9662 as follows. (1) telmisartan (5 mg/kg/day). For
hypertensive patients, telmisartan is orally administered
at the dose of 20‐160 mg per day, which is equivalent
to ≈ 0.3-3 mg/kg/day. A pharmacokinetic study showed
that steady state Cmax of telmisartan was 28.3 ng/ml at
20 mg and 592 ng/ml at 120 mg (≈ 0.06-1.15 μmol/L) in
normotensive elderly subjects [19]. We had preliminary
confirmed telmisartan show a PPAR-γ agonistic effect at
doses of 0.5-10 μM in HEK293 cells (data not shown).
Combined, we selected the dose of 5 mg/kg/day to ob-
tain a PPAR-γ agonistic effect at a clinical dose. (2)GW9662 (1 mg/kg/day). We determined the dose of
GW9662 following Goyal et al [20]. They showed that
the protective effects of telmisartan (10 mg/kg/day) on
myocardial infarction model in experimental diabetes
could be modulated by down-regulated PPAR-γ expres-
sion by 1 mg/kg/day of GW9662 [20].
Body weight, food intake, systolic blood pressure and
blood glucose were measured weekly. Blood pressure
was measured using a tail-cuff system (Softron, Co.,
Tokyo) and glucose was determined by a glucose oxidase
test. Mice were housed in a light- and temperature-
controlled room, with a 12-hour light/dark cycle.
At the end of the experimental period, an insulin toler-
ance test (ITT) was performed. Mice were given an
intraperitoneal injection of 0.75 U/kg insulin, after which
blood glucose concentrations were measured at 0, 15,
30, 60, and 120 min. Moreover, at the end of the experi-
mental period, serum, and subcutaneous and visceral fat,
were collected and stored at -80°C until assayed. Insulin
was determined by a mouse insulin ELISA kit (AKRIN-
011 T, Shibayagi, Gunma, Japan).
Distribution of adipocyte size was determined as previ-
ously described [21]. Briefly, adipocytes isolated from
visceral and subcutaneous adipose tissue were fixed with
2% osmium tetroxide and passed through a 250-μm
nylon filter to remove the fibrous elements, after which
the cells were washed extensively with isotonic saline.
10000 cells were analyzed using the Coulter Multisizer
III (Beckman Coulter, High Wycombe, England).
Paraffin-embedded serial sections of pancreata (5-μm
thickness) were stained for Hematoxylin and Eosin (HE)
and indirect insulin immunostaining [22].
Cell culture
C2C12 myoblasts were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma) with 4.5 g/L glucose sup-
plemented with 10% fetal bovine serum (FBS; Sigma), 100
U/mL penicillin, and 100 μg/mL streptomycin as previously
described [23]. One day after C2C12 myoblasts reached
confluence (day 0), cells were induced to differentiate into
myocytes by replacing the medium with a low serum differ-
entiation medium (2% horse serum; GibcoW, Life Tech-
nologies Japan, Ltd., Tokyo) for 2 days. After 48 h, the
induction medium was removed and cells were maintained
in DMEM with 10% FBS and, thereafter, the medium was
changed every 2 days until day 5. Telmisartan was dissolved
in dimethyl sulfoxide (DMSO) and added to culture media
within 0.1% of volume (telmisartan final concentration:
0 - 1 μM). Telmisartan treatment was performed on day 5.
NAD+/NADH measurements
NAD+ and NADH nucleotides were measured with an
enzymatic NADH recycling assay, using the NAD
+/NADH Quantification kit (BioVision, Mountain View,
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col [24]. C2C12 myotubes were collected in 200 μl of
NADH/NAD+ extraction buffer by subjecting the cells
to 2 cycles of freeze/thaw. The supernatants were
divided into 2 sets: to detect NADH, 1 set of superna-
tants was heated to 60°C for 30 min to decompose
NADH, while those from the other set was used to
measure the total NADH plus NAD+-content, by per-
forming the cycling assay in the absence of thermal de-
composition. Then, the NAD+/NADH ratio was
calculated.
Semi-quantitative RT-PCR analysis
Total RNA was isolated from C2C12 myotubes using
RNAiso plus (Takara Bio Inc., Shiga, Japan). Complemen-
tary DNA synthesis was performed, using a QuantiTectW
Reverse Transcription kit (SA Biosciences, Boston, MA),
from 1 μg of the extracted total RNA. Then, we performed
real-time RT-PCR with gene-specific primers and SYBR
green dye using an Applied Biosystems 7500 Real-Time
PCR System (Life Technologies Japan Ltd, Tokyo). The
forward (fwd) and reverse (rev) primer sequences were
as follows: Sirt1 (fwd: 50-TGCAGACGTGGTAATGTCCA
AAC-30; rev: 50-ACATCTTGGCAGTATTTGTGGTGA
A-30), GLUT4 (fwd: 50-TTTCCAGCAGATCGGCTCTG
ACGA-30; rev: 50-TAGCCAAACTGAAGGGAGCCAAG
C-30), ACO (fwd: 50-GGTTGTCATCGCTTTGGTGCC
TGT-30; rev: 50-TAACTCTGGATTGAAGGTGGCGGC
G-30), FATP-1 (fwd: 50-CGGTGTGGTGGCTGCTCTTC
TCAA-30; rev: 50-CGCTGCCATCTCCCCGCCATAAA
T-30), GAPDH (fwd: 50-CAAGGTCATCCATGACAACTT
TG-30; rev: 50-GGCCATCCACAGTCTTCTGG-30). The
reaction mixture containing reverse-transcribed cDNAs
was preheated for 10 min at 95°C to activate the Taq poly-
merase. Fifty cycles of PCR, each consisting of a 10-s de-
naturation step at 95°C, a 15-s annealing step at 60°C, and
a 15-s extension step at 72°C, was then performed.
Throughout real-time PCR analysis, product identities
were confirmed by melting curve analysis. The quantifica-
tion of each gene was determined relative to a standard
curve generated from a serially diluted sample. The ratios
of the amounts of target mRNA to the amount of the in-
ternal standard (GAPDH) mRNA was determined as an
arbitrary unit.
Western blotting
Whole cell lysates for western blotting were harvested in
RIPA buffer (Wako Pure Chemical Industries, Ltd.,
Tokyo) containing protease inhibitors (Takara Bio Inc.,
Shiga) and phosphatase inhibitor (Nacalai Tesque,
Kyoto, Japan). Protein concentrations in the superna-
tants were determined using the Bio-Rad protein assay
(Bio-Rad Laboratories, Inc., Tokyo). Twenty micrograms
of protein were separated on a 5–20% gradient SDS-PAGE gel (ATTO Corporation, Tokyo) and transferred
to polyvinylidene difluoride membranes (Millipore
Corp., Billerica, MA). Membranes were blocked for 1 h
at 20-25°C with 2% bovine serum albumin (BSA) or 5%
Skim milk tris buffer saline Tween 20 (TBST) buffer.
The membranes were incubated with appropriate dilu-
tions of the primary antibodies (Toyobo Co., Ltd.,
Tokyo), viz., anti-Adiponectin (PA1-054 [1:2500 dilution];
Thermo Fisher Scientific Inc., Rockford, Illinois), anti-
Phospho-AMPKα (Thr172) (2531 [1:5000 dilution]; Cell
Signaling Technology, Inc., Beverly, MA), anti-AMPKα
(2532 [1:5000 dilution]; Cell Signaling Technology, Inc.),
and anti-GAPDH (2118 [1:5000 dilution]; Cell Signaling
Technology, Inc.), overnight at 4°C. After washing, the
blots were then incubated with HRP-conjugated anti-
rabbit secondary antibody (7074 [dilution 1:5000], Cell
Signaling Technology, Inc.) for 1 h in a room with a
temperature maintained at 22 ± 2°C. Signals were detected
using the Amersham™ ECL™ Prime enhanced chemilumin-
escence system (GE Healthcare Japan, Tokyo) and LAS-
3000 mini imaging system (FujiFilm, Tokyo).Statistical analysis
All data are expressed as the means ± standard error
(SE). Statistical analysis was analyzed with Student’s t-
test for parametric comparison between 2 groups, or
analysis of variance (ANOVA) with post-hoc testing by
Fisher’s protected least significant difference (PLSD) test
for multiple comparisons. Values of p < 0.05 were con-
sidered statistically significant.Results
In vivo study
During the 5 weeks of the study period, db/db mice fed a
high-fat diet gained weight, irrespective of whether they
were treated with CMC, telmisartan, or telmisartan +
GW9662 (Figures 1A and B). Systolic blood pressure
remained unchanged in all groups during the study period
(Figure 1C). Overnight fasting glucose levels were higher in
the db/db mice than in the wild-type mice, but were not
different among the 3 treatment db/db groups (Figure 1D).
Plasma levels of adiponectin were not significantly different
among groups [wild-type 5.22 ± 0.49 μg/mL (n = 6), CMC
9.14 ± 2.88 (n = 5) telmisartan 9.09 ± 1.07 (n = 4), and tel-
misartan + GW9662 6.67 ± 0.49 (n = 4)].
The ITT at the end of the 5-week study period demon-
strated that the 120-min glucose levels were significantly
decreased in telmisartan-treated and telmisartan +
GW9662-treated mice as compared to CMC-treated mice
(Figure 1E). The baseline insulin levels, measured before
the ITT, had been comparable among the 3 db/db groups
(Figure 1F).
Figure 1 Effects of telmisartan on db/db mice fed a high-fat diet. In db/db mice fed a high-fat diet with CMC (○, n = 6), telmisartan (•, n = 6),
or telmisartan + GW9662 (△, n = 7) for 5 weeks, body weight (A), food intake (B), systolic blood pressure (C), blood glucose (D), glucose levels
during the insulin tolerance test (E), and fasting insulin levels (F) were measured. Values for wild type mice fed normal chow (□, n = 7) are also
shown for reference. Glucose levels during the insulin tolerance test were measured after intraperitoneal injection with 0.75 U/kg insulin. Values
shown represent means ± S.E. *p < 0.05 vs. 0 min and †p < wild type, by Fisher’s PLSD.
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expression
In skeletal muscle, expression of Sirt1mRNA was increased
in telmisartan-treated mice compared to CMC-treated
mice, but the expression was similar in telmisartan- and tel-
misartan + GW9662-treated mice (Figure 2). Expression of
PGC1α and GLUT4 mRNA was not different between
CMC-treated and telmisartan-treated mice.
In visceral adipose tissue (VAT) and subcutaneous adi-
pose tissue (SAT), expression of Sirt1, PGC1α, and
GLUT4 mRNA were profoundly decreased in CMC-
treated db/db mice as compared to wild type. The ex-
pression was comparable between telmisartan-treated
and telmisartan + GW9662-treated mice.Effects of telmisartan on the size of adipocytes and
pancreatic islets in db/db mice fed a high-fat diet
The mean size of adipocyte in VAT and SAT was ≈ 2
times larger in db/db mice as compared to wild type
(mean size of VAT 88 μm and SAT 94 μm). There
were no significant differences in the size distribution
(Figure 2) and the mean size among CMC-, telmisartan-,
and telmisartan + GW9662-treated mice: 171 μm,
179 μm, and 182 μm in VAT and 181 μm, 180 μm, and
178 μm in SAT. However, although pancreatic islet size
was increased in CMC-treated compared to wild-type
mice, it was significantly decreased in telmisartan- and
telmisartan + GW9662-treated mice (Figure 3).Effect of telmisartan on AMPK-SIRT1 pathway
Since telmisartan increased Sirt1 mRNA levels in the
skeletal muscle of db/db mice, we investigated whether
telmisartan administration could directly affect SIRT1
signals in C2C12 myoblasts. Treatment with telmisartan
increased Sirt1 mRNA in C2C12 cells (Figure 4A).
Treatment of C2C12 cells with telmisartan resulted in
activation of AMPK, by means of phosphorylation, to a
level comparable to that induced by 5-aminoimidazole-
4-carboxamide ribonucleoside (AICAR), an activator of
AMPK (Figure 4B). Treatment of C2C12 cells with tel-
misartan increased NAD+ and decreased NADH, result-
ing in an increase in the NAD+/NADH ratio, to a level
comparable to that induced by AICAR (Figure 4C).
Effect of telmisartan on mRNA expression of AMPK/SIRT1
pathway-related molecules in C2C12 myocytes
Treatment with telmisartan increased the mRNA levels
of PGC1, FATP1, ACO and GLUT4, but not of GLUT1,
in C2C12 myocytes (Figure 5).
Discussion
Here, we showed that telmisartan treatment improved
insulin sensitivity in obese db/db mice fed a high-fat diet
and led to reduction in the size of hypertrophic pancre-
atic islets in these mice. Moreover, we demonstrated that
in vitro treatment with telmisartan led to increased ex-
pression of Sirt1 mRNA in skeletal muscle cells; the in-
crease in Sirt1 mRNA in telmisartan-treated C2C12
Figure 2 Effects of telmisartan on mRNA expression and adipocyte size distribution in db/db mice fed a high-fat diet. At sacrificed after
5-week treatment, Sirt1, PGC1α, and GLUT4 mRNA expression were semi-quantified by RT-PCR in skeletal muscle and in visceral adipose tissue
(VAT) and subcutaneous adipose tissue (SAT). GAPDH was used as an internal control. Distribution of adipocyte size was determined by the
Coulter Multisizer III (Beckman Coulter, High Wycombe, England) after fixed with 2% osmium tetroxide. Values shown represent means ± S.E
(n = 3-4). *p < 0.05 vs. wild type and †p < 0.05 vs. CMC by Fisher’s PLSD.
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AMPK phosphorylation, an increase in NAD+/NADH
ratio, and increases in the mRNA levels of PGC1,
FATP1, ACO, and GLUT4.
It has previously been shown that levels of Sirt1 mRNA
and SIRT1 activity are decreased in an animal obesity model
[25,26] and in obese humans [27]. To investigate the poten-
tial consequences of decreased SIRT1, we utilized db/db
mice, a genetic model of obesity and insulin resistance
resulting from a leptin receptor mutation [28]. On a high-fat
diet, this db/db strain demonstrates severe insulin resistance
and hyperglycemia [29]. In the current study, all mice fed a
high-fat diet gained body weigh comparably (Figures 1A and
B) and casual glucose levels did not differ among the 3 treat-
ment groups (Figure 1D), but ITT-determined glucose levels
were significantly decreased in telmisartan-treated mice.
This indicates that administration of telmisartan ameliorates
insulin resistance in the obesity and insulin resistance model.
Because co-administration of GW9662, a selective PPARγ
inhibitor, could not reverse this in vivo effect of telmisartan,
the effects of telmisartan appear to act via a PPARγ-
independent pathway. It has been suggested that some of
angiotensin II receptor blockers (ARBs) have beneficial
effects on lipid metabolism [30] and insulin sensitivity pos-
sibly through PPAR-γ activation [9-13]. We confirmed that
0.5-10 μM of telmisartan, but not up to 10 μM of olmesar-
tan nor valsartan, have a PPAR-γ agonistic effect in HEK293
cells (data not shown). It should be clarified how differentARBs show mechanism(s) beyond blockade of renin-
angiotensin system (RAS) in future studies.
Since it has been reported that AMPK activity and SIRT1
expression are decreased in the white adipose tissue (WAT)
of db/db and HFD mice [26], we evaluated mRNA levels of
Sirt1, PGC1α, and GLUT4 in the VAT and SAT of the vari-
ous db/db mouse treatment groups. Consistent with a pre-
vious study [26], vehicle-treated db/db mice showed a
decreased expression of Sirt1, PGC1α, and GLUT4 mRNAs
in the VAT and SAT. Moreover, treatment with telmisartan
did not change these expression levels, suggesting that tel-
misartan improved insulin resistance via a non-adipose
tissue metabolic network in this db/db model. This hypoth-
esis is supported by the finding that the adipocyte size dis-
tribution was not changed by telmisartan treatment.
However, telmisartan administration did upregulate expres-
sion of Sirt1 mRNA and levels of phospho-Thr172-AMPK
in skeletal muscle.
Metabolic sensors such as AMPK and SIRT1 are the
gatekeepers of the activity of the master regulator, the
mitochondrion, and are crucial to the regulatory net-
work for metabolic homeostasis [1,31,32]. Mice models
mildly overexpressing SIRT1 demonstrated ameliorated
glucose tolerance when insulin resistance and/or dia-
betes were induced [33,34]. Similarly, treatment with dif-
ferent SIRT1 agonists prevents weight gain and insulin
resistance when mice were challenged with high-fat diets
[8,35]. Similarly, pharmacological activation of AMPK by
Figure 3 Effects of telmisartan on the morphology and mass of pancreatic islets in db/db mice fed a high-fat diet. Representative
sections of paraffin-embedded serial sections of pancreata (5-μm m thickness) in wild type mice or db/db mice fed a high-fat diet with CMC,
telmisartan, or telmisartan + GW9662 were stained for hematoxylin and eosin (HE). The size of pancreatic islets was determined from manually
traced islet area. Values shown represent means ± S.E (n = 115-150). †p < 0.05 vs. CMC by Fisher’s PLSD.
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sistance in animals fed a high-fat diet. These results indi-
cate a role for AMPK/SIRT1 in the control of metabolic
homeostasis. It is believed that metformin treatment is
the successful approach to reduce insulin resistance
mainly through activation of liver AMPK [6], whereas
DPP-4 inhibitors exhibit the best effects after oralFigure 4 Effects of telmisartan on the AMPK/SIRT1 pathway in C2C12
telmisartan and the level of Sirt1 mRNA measured by RT-PCR (A). On day 5, C2C
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMP-a
were subjected to western blot analysis using antibodies specific for Phospho-A
(C) in C2C12 myocytes treated with telmisartan or AICAR (0.5 mM). Values showglucose loading, emphasizing the incretin effect after
oral stimulation [36]. However, metformin and DPP-4
inhibitors may involve different mechanisms in the treat-
ment of mice fed high-fat diet [37]. Bourron et al. sug-
gested a possible role of metformin on AMPK
dependent lipolysis in adipocytes that may lead to lower
plasma levels of fatty acids and to alleviating insulinmyocytes. C2C12 myocytes were treated with vehicle or 0.01–0.1 μM
12 myocytes were treated with 0.1 μM telmisartan or 2 mM
ctivated protein kinase (AMPK), for 60 min, after which total cell lysates
MPK and total AMPK (B). NAD+, NADH content, and NAD+/NADH ratio
n represent means ± S.E (n = 3-5). *p < 0.05 vs. 0, by Fisher’s PLSD.
Figure 5 Effects of telmisartan on AMPK/SIRT1 pathway in C2C12 myocytes. On day 5, C2C12 myocytes were treated with telmisartan
(indicated concentrations) for 12 h and analyzed by semi-quantitative RT-PCR. GAPDH was used as an internal control. Values shown represent
the means ± S.E (n = 3-5). *p < 0.05 vs. 0 μM or baseline, by Fisher’s PLSD.
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efficiently and, even though the precise mechanisms re-
main to be elucidated, DPP-4 inhibition produced extra-
pancreatic effects, such as enhanced postprandial lipid
mobilization and oxidation [36]. Altogether, upregulation
of Sirt1 mRNA and activation of AMPK in the skeletal
muscle are associated with the improved insulin sensitiv-
ity observed upon telmisartan treatment.
PGC1α and GLUT4 mRNA expression also tended to
be increased in skeletal muscle cells. AMPK and SIRT1
have both been described to directly affect PGC-1α ac-
tivity through phosphorylation and deacetylation, re-
spectively [32]. Thus, we next evaluated the direct effect
of telmisartan on PGC-1α activity in muscle usingFigure 6 A model of the proposed mechanism by which
telmisartan improves insulin sensitivity in obese db/db mice.
Telm: telmisartan; ▲: site of action; Ac: acetylated;
P: phosphorylated; PGC1α: peroxisome proliferator-activated
receptor-γ coactivator-1α; PPRE: PPAR response element.C2C12 mouse myoblast cells. We found that in vitro
treatment with telmisartan increased Sirt1 mRNA con-
comitantly with the increase in AMPK phosphorylation,
an increase in the NAD+/NADH ratio, and the mRNA
levels of PGC1, FATP1, ACO, and GLUT4 in C2C12
cells. To our knowledge, the current study, for the first
time, showed that treatment with telmisartan enhanced
Sirt1 mRNA and protein in the skeletal muscle.
SIRT1, an NAD+-dependent regulator of energy me-
tabolism, has been reported to be activated through
AMPK-mediated induction of nicotinamide phosphori-
bosyltransferase (NAMPT), the rate-limiting enzyme for
NAD+ biosynthesis [1,8]. We thus examined the direct
effects of telmisartan on AMPK. Telmisartan resulted in
a significant increase in AMPKα phosphorylation at
Thr172, to a level comparable to that induced by
AICAR, an activator of AMPK.
Taken altogether, we propose a possible mechanism by
which telmisartan improves insulin sensitivity in skeletal
muscle in Figure 6D. Impaired adipocytokine signaling,
caused by suppression of expression of leptin and adipoR2
receptors, could lead to decreased activation of AMPK.
This, in turn, may result in decreased NAMPT transcrip-
tion, and consequently decreased SIRT1 activity and ex-
pression. Our results are also consistent with the notion
that telmisartan, besides blocking AT1, acts to promote
adipocyte differentiation and improve insulin sensitivity.
As previously reported, pancreatic islets in db/db mice
on a high-fat diet were profoundly hypertrophic, pre-
sumably as compensation for severe insulin resistance.
Saitoh et al. reported that telmisartan decreased the ac-
cumulation of palmitate-induced reactive oxygen species
in MIN6 cells by 25%, and by 55% in mouse islet cells,
suggesting that RAS blockade may be a possible
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insulin secretion capacity [39]. Yuan et al. reported that
telmisartan and perindopril, a RAS inhibitor, comparably
improved islet morphology, and significantly reduced
IL-1β, HIF-1α, and CHOP mRNA in Wistar rats fed a
high-fat diet for 16 weeks [40]. They suggested that
blockade of RAS may protect the islet function of rats
on a long-term high-fat diet, via down-regulation of islet
inflammation, oxidative stress, endoplasmic reticulum
stress, and apoptosis [41]. Our study showed that such
hypertrophic pancreatic islets were improved in telmi-
sartan-treated, and in telmisartan + GW9662-treated
mice. The distribution in pancreatic β cell mass may also
be affected by telmisartan, but we could not determine
variation in the β cell mass distribution by our method.
Although we could not determine the mechanism by
which telmisartan affects islet morphology and function,
future studies should determine the precise mechanism
of the antimetabolic effects of this drug.
Our study had some limitations. First, the C2C12 model
has limitations in comparison to freshly prepared frozen
skeletal muscle cells [23]: C2C12 cells were originally
obtained by Yaffe and Saxel through serial passage of myo-
blasts cultured from the thigh muscle of C3H mice after a
crush injury. C2C12 cells are a useful tool for studying the
differentiation of myoblasts and osteoblasts, expressing
various proteins, and exploring mechanistic pathways.
Nevertheless, the C2C12 cell line originated from a single
clone, and thus has clone-specific traits, and fails to recap-
itulate primary cells. Second, the use of a single concentra-
tion of GW9662 may not be specific for verifying inhibition
of PPARγ activity. We used a single dose of 1 mg/kg of
GW9662 for the in vivo studies, and a single dose of 5 μM
of GW9662 for the in vitro studies. We determined the
effect of telmisartan on the activity of a PPARγ2 pro-
moter luciferase gene reporter construct, indicating that
0.5–10.1 mM of telmisartan increased the activity of the
PPARγ2 gene promoter by 1.8- to 2-fold, to a ≃30% level
comparable to that achieved by pioglitazone, a known
PPARγ agonist (in submission). The effects of telmisartan
through PPARγ-dependent and -independent pathways
need to be confirmed in further studies. Third, nonspecific
effects of the drugs used in this study cannot be eliminated.
GW9662 has been shown to inhibit COX-2 activity in
addition to having an inhibitory effect on PPARγ, the active
derivative of AICAR modulates other AMP-sensitive
enzymes, and the selectivity of compound C for inhibition
of AMPK remains uncertain. The findings presented in this
study should be confirmed by using dominant-negative vec-
tors or siRNA knockdown of AMPK and SIRT1 in the fu-
ture. Fourth, our study could not determine whether
telmisartan regulates AMPK/SIRT1 pathways in a tissue-
or model-specific manner. Caton et al. reported that AMPK
activity, NAMPT expression and SIRT1 expression weredecreased in the WAT of db/db and HFD mice [26]. In
addition, they showed that metformin increased the AMPK
activity in the WAT of db/db mice and in adipocytes trea-
ted with metformin, with increased NAMPT and SIRT1
levels. In our study, telmisartan showed significant changes
in protein and mRNA levels in skeletal muscle, but not in
WAT. Although we cannot explain this discrepancy be-
tween the 2 studies, Chen et al. reported that SIRT1 expres-
sion is differentially regulated, in a tissue-specific manner
upon calorie restriction, which may reflect tissue-specific
roles of SIRT1 [41]. Tissue-specific effects of telmisartan
need to be elucidated in future studies. Finally, the estima-
tion of cell size has a limitation: in the fat pad, central adi-
pocytes are usually bigger than peripheral adipocytes, and
islets are roughly spheres and sections could cut spheres at
its poles and distort the results.
In conclusion, telmisartan treatment improved glucose
intolerance in db/db mice fed a high-fat diet, which was
not inhibited by GW9662 co-administration. Telmisar-
tan increased Sirt1 mRNA concomitantly with activation
of AMPK via phosphorylation, an increase in NAD
+/NADH ratio, and increase in mRNA levels of PGC1α,
FATP1, ACO, and GLUT4 in C2C12 cell lines, suggest-
ing that these improvements were at least partially due
to the direct actions of telmisartan on AMPK/SIRT1
pathways. Precise understanding of this molecular mech-
anism will require further investigations.
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